Continuous subcutaneous infusion of apomorphine in Parkinson's disease: Retrospective analysis of a series of 81 patients;Le traitement par apomorphine en perfusion continue sous-cutanée dans la maladie de Parkinson: analyse rétrospective d'une série de 81 patients

Revue Neurologique

Volumn 170, Issue 3, 2014, Pages 205-215

  Rambour, M ^a   Moreau, C ^a,b   Salleron, J ^c   Devos, D ^a,b   Kreisler, A ^a,d   Mutez, E ^a,d   Simonin, C ^a,d   Annic, A ^a   Dujardin, K ^a,b   Destee A ^a,d   Defebvre, L ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c UNIV LILLE   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

Apomorphine; Parkinson's Disease; Quality of life

Indexed keywords

APOMORPHINE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PARKINSON DISEASE; QUALITY OF LIFE; RETROSPECTIVE STUDY; UNIFIED PARKINSON DISEASE RATING SCALE; ADULT; AGED; CHEMICALLY INDUCED; DRUG ERUPTIONS; DRUG SCREENING; FEMALE; HALLUCINATION; MALE; MIDDLE AGED; PATIENT ATTITUDE; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIPARKINSON AGENTS; APOMORPHINE; DOPAMINE AGONISTS; DRUG ERUPTIONS; DRUG EVALUATION; FEMALE; HALLUCINATIONS; HUMANS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84897570657     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2013.10.012     Document Type: Article

References (28)

1. W. Poewe, and G.K. Wenning Apomorphine: an underutilized therapy for Parkinson's disease Mov Disord 15 2000 789 794
2. A.J. Hughes, S. Bishop, B. Kleedorfer, N. Turjanski, W. Fernandez, and A.J. Lees et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years Mov Disord 8 1993 165 170
3. K. Pietz, P. Hagell, and P. Odin Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow up J Neurol Neurosurg Psychiatry 65 1998 709 716
4. G.K. Wenning, S. Bösch, E. Luginger, M. Wagner, and W. Poewe Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease Adv Neurol 80 1999 545 548
5. P.J. Garcia Ruiz, A. Sesar Ignacio, B. Ares Pensado, A. Castro Garcia, F. Alonso Frech, and M. Alvarez Lopez et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study Mov Disord 23 2008 1130 1136
6. A.J. Manson, K. Turner, and A.J. Lees Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients Mov Disord 17 2002 1235 1241
7. F. Stocchi, L. Vacca, M.F. De Pandis, L. Barbato, M. Valente, and S. Ruggieri Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results Neurol Sci 22 2001 93 94
8. T. Van Laar, A.G. Postma, and M. Drent Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations Parkinsonism Relat Disord 16 2010 71 72
9. A.E. Di Rosa, A. Epifanio, A. Antonini, F. Stocchi, G. Martino, and B.L. Di et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease Neurol Sci 24 3 2003 174 175
10. S. Drapier, and M. Vérin L'apomorphine en perfusion sous-cutanée continue dans le traitement de la maladie de Parkinson Rev Neurol (Paris) 162 2006 1019 1023
11. C.E. Clarke, P. Worth, D. Grosset, and D. Stewart Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease Parkinsonism Relat Disord 15 2009 728 741
12. D. Nyholm, R. Constantinescu, B. Holmberg, N. Dizdar, and H. Askmark Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations Acta Neurol Scand 119 2009 345 348
13. A.J. Hughes, S.E. Daniel, L. Kifford, and A.J. Lees Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 1992 181 184
14. S. Fahn, and R.L. Elton Members of the UPDRS development committee. unified Parkinson's disease rating scale S. Fahn, D.B. Calne, M. Goldstein, Recent developments in Parkinson's disease 1987 Macmillan Health Care Information Florham Park, NJ 153 163
15. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 1967 427 442
16. N. Giladi, H. Shabtai, E.S. Simon, S. Biran, J. Tal, and A.D. Korczyn Construction of freezing of gait questionnaire for patients with Parkinsonism Parkinsonism Relat Disord 6 2000 165 170
17. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change Br J Psychiatry 134 1979 382 389
18. P. Sockeel, K. Dujardin, D. Devos, C. Denève, A. Destée, and L. Defebvre The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease J Neurol Neurosurg Psychiatry 77 2006 579 584
19. V. Voon, K. Hassan, M. Zurowski, M. de Souza, T. Thomsen, and S. Fox et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease Neurology 67 2006 1254 1257
20. S.L. McElroy, P.E. Keck, H.G. Pope, J.M. Smith, and S.M. Strakowski Compulsive buying: a report of 20 cases J Clin Psychiatry 55 1994 242 248
21. G. Giovannoni, J.D. O'Sullivan, K. Turner, A.J. Manson, and A.J. Lees Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies J Neurol Neurosurg Psychiatr 68 2000 423 428
22. C. Jenkinson, R. Fitzpatrick, V. Peto, R. Greenhall, and N. Hyman The Parkinson's disease questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score Age Ageing 26 1997 353 357
23. T.M. Cutson, R. Sloane, and M. Schenkman Development of a clinical rating scale for persons with Parkinson's disease J Am Geriatric Soc 47 1999 763 764
24. A. Antonini, I.U. Isaias, G. Rodolfi, A. Landi, F. Natuzzi, and C. Siri et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation J Neurol 258 2011 579 585
25. A. Antonini, and P. Odin Pros and cons of apomorphine and L-Dopa continuous infusion in advanced Parkinson's disease Parkinsonism Relat Disord 15 2009 97 100
26. S. Drapier, A.S. Gillioz, E. Leray, J. Péron, T. Rouaud, and A. Marchand et al. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications Parkinsonism Relat Disord 18 2012 40 44
27. R. Katzenschlager, A. Hughes, A. Evans, A.J. Manson, M. Hoffman, and L. Swinn et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges Mov Disord 20 2 2005 151 157
28. H.L. Tyne, J. Parsons, A. Sinnott, S.H. Fox, N.A. Fletcher, and M.J. Steiger A 10-year retrospective audit of long-term apomorphine use in Parkinson's disease J Neurol 251 2004 1370 1374